The homocysteine hypothesis: Still relevant to the prevention and treatment of cardiovascular disease?

Cleveland Clinic Journal of Medicine

Volumn 77, Issue 12, 2010, Pages 911-918

  Abraham, Joellyn M ^a   Cho, Leslie ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN B COMPLEX;

BLOOD; CARDIOVASCULAR DISEASE; ENZYMOLOGY; HUMAN; HYPERHOMOCYSTEINEMIA; METABOLISM; PRIMARY PREVENTION; REVIEW;

CARDIOVASCULAR DISEASES; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; PRIMARY PREVENTION; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 78650387370     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.77a.10036     Document Type: Review

References (64)

1. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008; 83:1203-1212.
2. Boers GH. The case for mild hyperhomocysteinaemia as a risk factor. J Inherit Metab Dis 1997; 20:301-306.
3. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 2004; 11(suppl 1):S56-S64.
4. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008; 299:2027-2036.
5. Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008; 300:795-804.
6. Butz LW, du Vigneaud V. The formation of a homologue of cystine by the decompensation of methionine with sulphuric acid. J Biol Chem 1932; 99:135-142.
7. Gibson JB, Carson NA, Neill DW. Pathological findings in homocystinuria. J Clin Pathol 1964; 17:427-437.
8. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56:111-128.
9. Zhang D, Jiang X, Fang P, et al. Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine beta-synthase-deficient mice. Circulation 2009; 120:1893-1902.
10. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 1999; 34:2002-2006.
11. Righetti M, Ferrario GM, Milani S, et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 2003; 9:PI19-PI24.
12. Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006; 47:1108-1116.
13. Carmel R, Jacobsen DW, editors. Homocysteine in Health and Disease. Cambridge, UK: Cambridge University Press, 2001.
14. Yap S, Boers GH, Wilcken B, et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 2001; 21:2080-2085.
15. McKusick V. 236200 Homocystinuria. In: McKusick V, editor. Mendelian Inheritance in Man. 10th ed. Baltimore, MD: The Johns Hopkins University Press, 1992:1444-1446.
16. McKusick V. 236250 Homocystinuria due to deficiency of N(5,10)- methylenetetrahydrofolate reductase activity. In: McKusick V, editor. Mendelian Inheritance in Man. Baltimore, MD: The Johns Hopkins University Press, 1992:1447-1448.
17. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202.
18. Nygård O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274:1526-1533.
19. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288:2023-2031.
20. Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C-->T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002; 59:529-536.
21. Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005; 331:1053.
22. Brattström L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98:2520-2526.
23. Cui R, Iso H, Date C, Kikuchi S, Tamakoshi A; Japan Collaborative Cohort Study Group. Dietary folate and vitamin B6 and B12 intake in relation to mortality from cardiovascular diseases: Japan Collaborative Cohort Study. Stroke 2010; 41:1285-1289.
24. Liu S, Stampfer MJ, Hu FB, et al. Whole-grain consumption and risk of coronary heart disease: results from the Nurses' Health Study. Am J Clin Nutr 1999; 70:412-419.
25. Liu S, Manson JE, Stampfer MJ, et al. Whole grain consumption and risk of ischemic stroke in women: a prospective study. JAMA 2000; 284:1534-1540.
26. Merchant AT, Hu FB, Spiegelman D, Willett WC, Rimm EB, Ascherio A. The use of B vitamin supplements and peripheral arterial disease risk in men are inversely related. J Nutr 2003; 133:2863-2867.
27. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279:359-364.
28. US Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151:474-482.
29. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the US Preventive Services Task Force. Ann Intern Med 2009; 151:496-507.
30. Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2009; (4):CD006612.
31. Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 2006; 24:379-386.
32. Mager A, Orvin K, Koren-Morag N, et al. Impact of homocysteinelowering vitamin therapy on long-term outcome of patients with coronary artery disease. Am J Cardiol 2009; 104:745-749.
33. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group; Armitage JM, Bowman L, Clarke RJ, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010; 303:2486-2494.
34. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. JAMA 2002; 288:973-979.
35. Lange H, Suryapranata H, De Luca G, et al. Folate therapy and instent restenosis after coronary stenting. N Engl J Med 2004; 350:2673-2781.
36. Khandanpour N, Armon MP, Jennings B, et al. Randomized clinical trial of folate supplementation in patients with peripheral arterial disease. Br J Surg 2009; 96:990-998.
37. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15:420-426.
38. Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N Engl J Med 2006; 354:1629-1632.
39. Bønaa KH, Njølstad I, Ueland PM, et al; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354:1578-1588.
40. Carrero JJ, López-Huertas E, Salmerón LM, Baró L, Ros E. Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J Nutr 2005; 135:1393-1399.
41. Liem AH, van Boven AJ, Veeger NJ, et al; Folic Acid on Risk Diminishment After Acute Myocarial Infarction Study Group. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. Int J Cardiol 2004; 93:175-179.
42. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: results of the Goes extension study. Heart 2005; 91:1213-1214.
43. Lonn E, Yusuf S, Arnold MJ, et al; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354:1567-1577.
44. Sydow K, Schwedhelm E, Arakawa N, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003; 57:244-252.
45. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291:565-575.
46. Jamison RL, Hartigan P, Kaufman JS, et al; Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007; 2989:1163-1170.
47. Erratum in JAMA 2008; 300:170.
48. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006; 296:2720-2726.
49. Namazi MH, Motamedi MR, Safi M, Vakili H, Saadat H, Nazari N. Efficacy of folic acid therapy for prevention of in-stent restenosis: a randomized clinical trial. Arch Iran Med 2006; 9:108-110.
50. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345:1593-1600.
51. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369:1876-1882.
52. Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis. Stroke 2010; 41:1205-1212.
53. Khandanpour N, Loke YK, Meyer FJ, Jennings B, Armon MP. Homocysteine and peripheral arterial disease: systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2009; 38:316-322.
54. Hansrani M, Stansby G. Homocysteine lowering interventions for peripheral arterial disease and bypass grafts. Cochrane Database Syst Rev 2002; (3):CD003285.
55. Mosca L. Novel cardiovascular risk factors: do they add value to your practice? Am Fam Physician 2003; 67:264, 266.
56. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-STelevation myocardial infarction. J Am Coll Cardiol 2007; 50:e1-e157.
57. Lonn E. Homocysteine-lowering B vitamin therapy in cardiovascular prevention-wrong again? JAMA 2008; 299:2086-2087.
58. Milani RV, Lavie CJ. Homocysteine: the Rubik's cube of cardiovascular risk factors. Mayo Clin Proc 2008; 83:1200-1202.
59. Bazzano LA. Folic acid supplementation and cardiovascular disease: the state of the art. Am J Med Sci 2009; 338:48-49.
60. Ntaios G, Savopoulos C, Grekas D, Hatzitolios A. The controversial role of B-vitamins in cardiovascular risk: an update. Arch Cardiovasc Dis 2009; 102:847-854.
61. Mosca L, Banka CL, Benjamin EJ; Expert Panel/Writing Group. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007; 115:1481-1501.
62. Bassuk SS, Albert CM, Cook NR, et al. The Women's Antioxidant Cardiovascular Study: design and baseline characteristics of participants. J Womens Health (Larchmt) 2004; 13:99-117.
63. SEARCH Study Collaborative Group; Bowman L, Armitage J, Bulbulia R, Parish S, Collins R. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J 2007; 154:815-823, 823.e1-e6.
64. Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 2009; 302:2119-2126.